These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 34198310)

  • 21. Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
    Modica S; Rossetti B; Lombardi F; Lagi F; Maffeo M; D'Autilia R; Pecorari M; Vicenti I; Bruzzone B; Magnani G; Paolucci S; Francisci D; Penco G; Sacchini D; Zazzi M; De Luca A; Di Biagio A
    HIV Med; 2019 Feb; 20(2):137-146. PubMed ID: 30461149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naïve and -experienced patients.
    Brehm TT; Franz M; Hüfner A; Hertling S; Schmiedel S; Degen O; Kreuels B; Schulze Zur Wiesch J
    Medicine (Baltimore); 2019 Aug; 98(32):e16721. PubMed ID: 31393378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.
    Bourgi K; Rebeiro PF; Turner M; Castilho JL; Hulgan T; Raffanti SP; Koethe JR; Sterling TR
    Clin Infect Dis; 2020 Mar; 70(7):1267-1274. PubMed ID: 31100116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.
    Scutari R; Alteri C; Vicenti I; Di Carlo D; Zuccaro V; Incardona F; Borghi V; Bezenchek A; Andreoni M; Antinori A; Perno CF; Cascio A; De Luca A; Zazzi M; Santoro MM;
    J Glob Antimicrob Resist; 2020 Mar; 20():163-169. PubMed ID: 31330378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance.
    Mbhele N; Chimukangara B; Gordon M
    Int J Antimicrob Agents; 2021 May; 57(5):106343. PubMed ID: 33852932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Might dolutegravir be part of a functional cure for HIV?
    Wainberg MA; Han YS; Mesplède T
    Can J Microbiol; 2016 May; 62(5):375-82. PubMed ID: 27031127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I: Impact in low-and middle-income settings.
    Ndashimye E; Arts EJ
    Int J Infect Dis; 2021 Apr; 105():298-303. PubMed ID: 33722682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on raltegravir and the development of new integrase strand transfer inhibitors.
    Shamroe CL; Bookstaver PB; Rokas KE; Weissman SB
    South Med J; 2012 Jul; 105(7):370-8. PubMed ID: 22766666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA).
    Rusconi S; Adorni F; Tau P; Borghi V; Pecorari M; Maserati R; Francisci D; Monno L; Punzi G; Meraviglia P; Paolucci S; Di Biagio A; Bruzzone B; Mancon A; Micheli V; Zazzi M;
    J Clin Virol; 2018 Aug; 105():112-117. PubMed ID: 29957545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV-1 resistance and virological failure to treatment with the integrase inhibitors bictegravir, cabotegravir, and dolutegravir: a systematic literature review.
    Blanco-Arévalo JL; García-Deltoro M; Torralba M; Vélez-Díaz-Pallarés M; Castro A; Rubio-Rodríguez D; Rubio-Terrés C
    AIDS Rev; 2024; 26(2):67-79. PubMed ID: 39134019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa.
    Salou M; Butel C; Comlan AS; Konou AA; Tegueni K; Ehlan A; Lack F; Dossim S; Ayouba A; Delaporte E; Dagnra AY; Peeters M
    AIDS; 2020 Apr; 34(5):783-787. PubMed ID: 31895149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of different integrase strand transfer inhibitors on body weight in patients with HIV/AIDS: a network meta-analysis.
    Bai R; Lv S; Wu H; Dai L
    BMC Infect Dis; 2022 Feb; 22(1):118. PubMed ID: 35114968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study.
    Santos JR; Casadellà M; Noguera-Julian M; Micán-Rivera R; Domingo P; Antela A; Portilla J; Sanz J; Montero-Alonso M; Navarro J; Masiá M; Valcarce-Pardeiro N; Ocampo A; Pérez-Martínez L; García-Vallecillos C; Vivancos MJ; Imaz A; Iribarren JA; Hernández-Quero J; Villar-García J; Barrufet P; Paredes R;
    Front Cell Infect Microbiol; 2023; 13():1187999. PubMed ID: 37434782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is There a Safety Signal for Dolutegravir and Integrase Inhibitors During Pregnancy?
    Chouchana L; Beeker N; Treluyer JM
    J Acquir Immune Defic Syndr; 2019 Aug; 81(4):481-486. PubMed ID: 31021990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitors.
    Weber J; Rose JD; Vazquez AC; Winner D; Margot N; McColl DJ; Miller MD; Quiñones-Mateu ME
    PLoS One; 2013; 8(6):e65631. PubMed ID: 23776513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
    Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
    BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
    Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
    J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Durability of Integrase STrand Inhibitor (InSTI)-based regimen in geriatric people living with HIV in the GEPPO cohort.
    Focà E; Calcagno A; Calza S; Renzetti S; Chiesa A; Siano M; De Socio G; Piconi S; Orofino G; Madeddu G; Cattelan AM; Nozza S; Ferrara M; Milic J; Celesia BM; Castelli F; Guaraldi G
    PLoS One; 2021; 16(10):e0258533. PubMed ID: 34644336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review.
    Chu C; Tao K; Kouamou V; Avalos A; Scott J; Grant PM; Rhee SY; McCluskey SM; Jordan MR; Morgan RL; Shafer RW
    Viruses; 2024 Mar; 16(3):. PubMed ID: 38543764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weight Gain Among Treatment-Naïve Persons With HIV Receiving Dolutegravir in Kenya.
    Bourgi K; Ofner S; Musick B; Griffith B; Diero L; Wools-Kaloustian K; Yiannoutsos CT; Gupta SK
    J Acquir Immune Defic Syndr; 2022 Dec; 91(5):490-496. PubMed ID: 36126175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.